The FY20 PRCRP Translational Team Science Award (TTSA) supports hypothesis-driven translational studies. These studies should be associated with clinical trial. The proposed project should focus on research for the next-phase clinical trial or future clinical application. The TTSA is intended to support advanced translational studies that are based on results from clinical investigations. While funding for clinical trials is allowed, the TTSA is intended to support multi-investigator, multidisciplinary teams to perform clinical research studies and not only to fund a clinical trial. Research projects funded by the TTSA should address critical knowledge gaps in clinical outcomes, validate key research results, expand upon potentially game-changing results, or investigate novel clinical findings.
The FY20 PRCRP TTSA Areas of Emphasis (strongly encouraged but not required):
· Interventions to improve quality of life for cancer patients and/or survivors
· Cancer prevention or early detection
Applications proposing a study not within the scope of the FY20 PRCRP TTSA Areas of Emphasis must demonstrate that the research proposed once translated to the clinic will have lasting impact in the research area studies.
The TTSA may support studies in animal models, human subjects, and human anatomical substances but must be related to a clinical trial (ongoing or complete). Accordingly, the use of relevant preclinical models may be included. The TTSA is not intended to support high-throughput screenings, sequencing, etc.
A Congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference- Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY20 PRCRP priorities.